News Releases

Date	Title and Summary	View
February 16, 2023	KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...	Additional Formats PDF Version
February 14, 2023	KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development - Phase 3 KONFIDENT clinical trial passes 50% enrollment milestone - - Topline data still expected in H2 2023 - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 14, 2023-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...	Additional Formats PDF Version
February 10, 2023	KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 10, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from...	Additional Formats PDF Version
February 7, 2023	KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session – Oral sebetralstat regimen for short-term prophylaxis to be evaluated in KONFIDENT-S – – Positive phase 1 sebetralstat data supports KONFIDENT trial expansion to Japan – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 7, 2023-- KalVista Pharmaceuticals, Inc....	Additional Formats PDF Version
February 3, 2023	KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 3, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...	Additional Formats PDF Version
February 2, 2023	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of...	Additional Formats PDF Version
January 5, 2023	KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President - Expanded role to lead business and commercial growth – - Follows $58 million financing in December 2022 led by top-tier syndicate – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 5, 2023-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company...	Additional Formats PDF Version
January 4, 2023	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 4, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 1,000 shares of...	Additional Formats PDF Version